These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15630904)

  • 1. Iron supplementation in adolescent hemodialysis patients.
    Nailescu C; Castaneda M; Del Rio M; Flynn JT
    Clin Nephrol; 2004 Dec; 62(6):449-54. PubMed ID: 15630904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
    Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
    Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
    Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
    Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of serum ferritin and transferrin saturation values associated with two i.v. iron formulations in hemodialysis patients.
    Nguyen TV
    Am J Health Syst Pharm; 2009 Jun; 66(12):1101-4. PubMed ID: 19498125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation.
    Fishbane S; Frei GL; Maesaka J
    Am J Kidney Dis; 1995 Jul; 26(1):41-6. PubMed ID: 7611266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of an intravenous iron dextran regimen on iron stores, hemoglobin, and erythropoietin requirements in hemodialysis patients.
    Park L; Uhthoff T; Tierney M; Nadler S
    Am J Kidney Dis; 1998 May; 31(5):835-40. PubMed ID: 9590194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
    Riedel MK; Morgenstern T
    Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of intravenous administration of Fe-gluconate-Na complex to maintain adequate body iron stores in hemodialysis patients.
    Navarro JF; Teruel JL; Liaño F; Marcén R; Ortuño J
    Am J Nephrol; 1996; 16(4):268-72. PubMed ID: 8739277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
    Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
    J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A study of parenteral iron regimens in hemodialysis patients.
    Besarab A; Kaiser JW; Frinak S
    Am J Kidney Dis; 1999 Jul; 34(1):21-8. PubMed ID: 10401011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse events in chronic hemodialysis patients receiving intravenous iron dextran--a comparison of two products.
    McCarthy JT; Regnier CE; Loebertmann CL; Bergstralh EJ
    Am J Nephrol; 2000; 20(6):455-62. PubMed ID: 11146312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achieving target hematocrit in dialysis patients: new concepts in iron management.
    Nissenson AR
    Am J Kidney Dis; 1997 Dec; 30(6):907-11. PubMed ID: 9398140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional iron deficiency in hemodialysis patients with high ferritin.
    Kopelman RC; Smith L; Peoples L; Biesecker R; Rizkala AR
    Hemodial Int; 2007 Apr; 11(2):238-46. PubMed ID: 17403177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness impact of iron dextran on hemodialysis patients' use of epoetin alfa and blood.
    Driver PS
    Am J Health Syst Pharm; 1998 Dec; 55(24 Suppl 4):S12-6. PubMed ID: 9872688
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preliminary experience on the use of sucrosomial iron in hemodialysis: focus on safety, hemoglobin maintenance and oxidative stress.
    Reggiani F; Colombo G; Astori E; Landoni L; Finazzi S; Milzani A; Angelini C; Dalle-Donne I; Cucchiari D
    Int Urol Nephrol; 2022 May; 54(5):1145-1153. PubMed ID: 34510284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.
    Michael B; Coyne DW; Fishbane S; Folkert V; Lynn R; Nissenson AR; Agarwal R; Eschbach JW; Fadem SZ; Trout JR; Strobos J; Warnock DG;
    Kidney Int; 2002 May; 61(5):1830-9. PubMed ID: 11967034
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sodium ferric gluconate therapy in renal transplant and renal failure patients.
    Yorgin PD; Belson A; Sarwal M; Alexander SR
    Pediatr Nephrol; 2000 Dec; 15(3-4):171-5. PubMed ID: 11149105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ferric gluconate treatment provides cost savings in patients with high ferritin and low transferrin saturation.
    Pizzi LT; Bunz TJ; Coyne DW; Goldfarb DS; Singh AK
    Kidney Int; 2008 Dec; 74(12):1588-95. PubMed ID: 19034302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative response to single or divided doses of parenteral iron for functional iron deficiency in hemodialysis patients receiving erythropoietin (EPO).
    Saltissi D; Sauvage D; Westhuyzen J
    Clin Nephrol; 1998 Jan; 49(1):45-8. PubMed ID: 9491286
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-molecular-weight iron dextran in the management of renal anaemia in patients on haemodialysis--the IDIRA Study.
    Rath T; Florschütz K; Kalb K; Rothenpieler U; Schletter J; Seeger W; Zinn S
    Nephron Clin Pract; 2010; 114(1):c81-8. PubMed ID: 19887827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.